Control of obesity inA vy /a mice by 5α-androstan-17-one

Yen, Terence T.; Allan, J. A.; Pearson, D; Acton, J M

doi:10.1007/bf02034660

Cited by 9 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings in this study support the antiobesity activity of DHEA observed in our previous study in sponta-neously obese dogs (1 8), as well as the findings reported of many studies in mice, rats, and humans (2,7,34). Studies in several strains of mice reported that DHEA administration resulted in a decreased weight gain without a reduction in food intake (36,38,49,50). Similar findings were reported in genetically obese Zucker rats (8,9,33).…”

Section: Discussionsupporting

confidence: 91%

“…Dehydroepiandrosterone (DHEA) is a 17-ketosteroid of adrenal and gonadal origin and, in its sulfated form (DHEAS), is the most abundant steroid circulating in human plasma (1 I). In humans, concentrations of DHEAS undergo the most marked age-related decline of any steroid, peaking at around 20 years of age, progressively declining with age, and becoming constant at 50 years to 80 years of age (27,35,49). DHEA is the main precursor of placental estrogen and may be converted to active androgens and estrogen in peripheral tissue, although its biological role remains unclear ( I 1, 37).…”

Section: Introductionmentioning

confidence: 99%

“…DHEA is the main precursor of placental estrogen and may be converted to active androgens and estrogen in peripheral tissue, although its biological role remains unclear ( I 1, 37). Early studies in obese mice and more recent studies in obese rats stimulated interest in the use of DHEA as an antiobesity agent (2,(7)(8)(9)(10)29,49,50). In a previous study, we showed that 13 (68%) of 19 spontaneously obese, euthyroid dogs treated with DHEA for 3 months lost 3% of their total bodyweight per month, without a reduction in food intake.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Effect of Dehydroepiandrosterone Combined with a Low‐Fat Diet in Spontaneously Obese Dogs: A Clinical Trial

Id¹,

Dl²,

Jb³

et al. 1998

Obesity Research

View full text Add to dashboard Cite

KURZMAN, ILENE D, DAVID L PANCIERA, JAMES B MILLER, E GREGORY MacEWEN. The effect of dehydroepiandrosterone combined with a low-fat diet in spontaneously obese dogs: A clinical trial. Obes Res. 1997;6:20-28. Dehydroepiandrosterone (DHEA) has been shown to have antiobesity activity in rodents and spontaneously obese dogs. This study evaluated the effect of DHEA or placebo combined with a low-fathigh-fiber diet in spontaneously obese dogs in a clinical trial. Spontaneously obese, euthyroid dogs, referred to the University of Wisconsin School of Veterinary Medicine for treatment of their obesity, were evaluated for percent overweight, rate of weight loss, serum cholesterol, plasma lipoprotein and serum biochemistry profiles, complete blood count, and endocrine profiles (T4, T3, cortisol, insulin, and DHEA-sulfate). DHEA-treated dogs had a significantly increased rate of actual and percent excess weight loss compared with placebo-treated dogs. Serum cholesterol decreased in both treatment groups; however, DHEA-treated dogs had a significantly greater reduction than placebo-treated dogs. DHEA-treated dogs had a significant 32% reduction in total plasma cholesterol, which was due to a 27% reduction in the lipoprotein fraction containing the high-density lipoprotein (HDL) and a 50% reduction in the lipoprotein fraction containing the low-density lipoprotein (LDL). Placebo-treated dogs did not have a significant reduction in total plasma cholesterol or in the fraction containing LDL; however, they did have a significant 11 % reduction in the fraction containing HDL. Significant decreases in serum T4 and T3 observed in dogs receiving DHEA were not noted in dogs receiving placebo. DHEA in combination with caloric restriction results in a faster rate of weight loss than does caloric restriction alone. In addition, DHEA has hypocholesterolemic activity, particularly affecting the lipoprotein fraction containing the LDL cholesterol.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Dehydroepiandrosterone Combined with a Low‐Fat Diet in Spontaneously Obese Dogs: A Clinical Trial

Id¹,

Dl²,

Jb³

et al. 1998

Obesity Research

View full text Add to dashboard Cite

show abstract

“…Earlier various authors have reported that the saponins showed strong inhibitory effects on the lipase secreted from the pancreas in vitro and prevented an increase in body weight which was induced by HF diet in vivo [34][35][36]. Yen et al [37] reported that 500 mg/kg dehydroepiandrosterone administered three times weekly to mice resulted in decreased weight gain by obese mice without affecting their food intake, they also showed an inhibitory effect of the steroid on fatty acid synthesis. Thus, solasodine (a saponin) might be responsible for the reduction in weight gain as compared to animals in HF control group.…”

Section: Fig 6: Effect Of Solasodine On Histopathology Of Liver In Rmentioning

confidence: 98%

Evaluation of Anti-Obesity Activity of Solasodine in High Fat Diet-Induced Obesity in Rat

Khaserao

Somani

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: This study was planned to study the anti-obesity activities of solasodine on high fat (HF) diet-induced obese rats.Methods: Wistar rats were divided into six groups. Control group (Group 1) received normal diet and 0.5 % CMC (5 ml/kg). HF control group (Group 2) received HF diet. Group 3 received orlistat (25 mg/kg body weight per oral). Group 4, 5 and 6 received 25, 50 and 100 mg/kg body weight solasodine respectively. Treatment was given for 6 w to the respective group along with HF diet. Body weight, food intake and abdomen circumference was measured every week for 6 w. On day 42, the serum biochemical parameters like blood glucose and insulin, serum leptin, total cholesterol and triglyceride were evaluated. Animals were sacrificed with overdose of diethyl ether. The liver and retroperitoneal adipose tissues were removed and weighed immediately. Results:Treatment with solasodine at dose of 50 mg/kg and 100 mg/kg significantly (p<0.001) reduced body weight, abdomen circumference and retroperitoneal adipose tissue weight as compared to the HF diet control group. Solasodine also significantly reduced serum total cholesterol, triglyceride and glucose level as compared to HF diet control group (***p<0.001, **p<0.01, *p<0.05 when compared with normal control. ###p<0.001, #p<0.05 when compared with high fat control). In addition, it also inhibited the induction of fatty liver with accumulation of hepatic triglyceride. Conclusion:Solasodine exhibited anti-obesity effect by showing a reduction in body weight, abdomen circumference, total cholesterol level, triglyceride level and glucose level in high-fat diet fed rats.

show abstract

“…Administration of DHEA to metabolically obese mice bearing the A vy /a mutation, significantly inhibited their weight gain (36). Measurements of food consumption showed that treated and untreated mice consumed equivalent amounts of food but that the DHEA-treated mice weighed less.…”

Section: Obesitymentioning

confidence: 99%

The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging

Williams

2000

Lipids

View full text Add to dashboard Cite

With the passage of the U.S. Dietary Supplement Health and Education Act of 1994, dehydroepiandrosterone (DHEA, 5-androsten-3beta-ol-17-one) has become widely available, and a large and growing market has developed for this "fountain of youth." DHEA has been shown to have significant beneficial effects in animals, which may lead to clinical uses in man. Historically, the U.S. Food and Drug Administration removed DHEA from the over-the-counter market in 1985 because there was no support for the health claims that were made for this product. Almost all of the biological data was on animals and there was a lack of demonstrated efficacy in humans. Recently there have been a number of small clinical trials in humans but the results have not been as positive as in the animal tests. This review will be restricted to the effects of DHEA on carcinogenesis, obesity, the immune system, and aging. Four hypotheses have been proposed to explain the underlying biochemical mechanism(s) by which DHEA exerts its beneficial properties. The first is based on the inhibitory effect of DHEA on mammalian glucose-6-phosphate dehydrogenase. This mechanism can explain the antiinitiation and antipromotion steps in some cases of carcinogenesis. The second biochemical mechanism involves the induction of peroxisomes and peroxisome-associated enzymes. The third explanation is that DHEA works in a similar fashion to the known anticarcinogenic action of food restriction. An antiglucocorticoid mechanism has also been suggested. A hypothesis for the increase followed by the decrease in the levels of DHEA with age is proposed. A number of new synthetic DHEA analogs have been synthesized and tested. They offer the best hope for the development of a clinically useful drug based on the properties of DHEA.

show abstract

Control of obesity inA vy /a mice by 5α-androstan-17-one

Cited by 9 publications

References 4 publications

The Effect of Dehydroepiandrosterone Combined with a Low‐Fat Diet in Spontaneously Obese Dogs: A Clinical Trial

The Effect of Dehydroepiandrosterone Combined with a Low‐Fat Diet in Spontaneously Obese Dogs: A Clinical Trial

Evaluation of Anti-Obesity Activity of Solasodine in High Fat Diet-Induced Obesity in Rat

The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging

Contact Info

Product

Resources

About